AavantiBio's vision is to harness the transformative science of gene transfer therapy and gene editing technologies to improve the lives of people living with fatal diseases. Founded by distinguished gene therapy researchers out of the University of Florida, the Company is advancing a pipeline of innovative gene transfer therapies in areas of high unmet medical need, which have the potential to become the next generation of life-changing medicines.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/22/20 | $107,000,000 | Series A |
Bain Capital Life Sciences Perceptive Advisors RA Capital Management Sarepta Therapeutics | undisclosed |
